Treatment of cutaneous lupus

Current Rheumatology Reports

Volumn 13, Issue 4, 2011, Pages 300-307

  Chang, Aileen Y ^a   Werth, Victoria P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antimalarials; CLASI; Cutaneous lupus erythematosus; Cutaneous lupus erythematosus disease area and severity index; Immunomodulators; Immunosuppressives; Topical calcineurin inhibitors; Topical steroids; Treatment

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLOROQUINE; CLOBETASOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; DEXAMETHASONE 17 VALERATE; HYDROXYCHLOROQUINE; IMIQUIMOD; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; LEFLUNOMIDE; LENALIDOMIDE; MEPACRINE; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PLACEBO; RITUXIMAB; SALBUTAMOL; STEROID; SUNSCREEN; TACROLIMUS; THALIDOMIDE; TOPICAL AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTICLE; BURNING SENSATION; CLINICAL ASSESSMENT; CONSTIPATION; CRYOTHERAPY; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DOSE RESPONSE; DROWSINESS; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEVER; GASTROINTESTINAL SYMPTOM; HAIR DISCOLORATION; HEADACHE; HEMOLYSIS; HUMAN; HYPERPIGMENTATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FAILURE; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; METHEMOGLOBINEMIA; MYOPATHY; PANNICULITIS; PERIPHERAL NEUROPATHY; PHOCOMELIA; PROTECTIVE CLOTHING; PRURITUS; RADIATION EXPOSURE; RASH; RETINA DISEASE; ROSACEA; SKIN ATROPHY; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; SYSTEMIC DISEASE; SYSTEMIC THERAPY; TELANGIECTASIA; THROMBOEMBOLISM; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT;

EID: 85027946120     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0180-z     Document Type: Article

References (52)

1. JN Gilliam RD Sontheimer 1981 Distinctive cutaneous subsets in the spectrum of lupus erythematosus J Am Acad Dermatol 4 471 475 7229150 10.1016/S0190-9622(81)80261-7 1:STN:280:DyaL3M7pt1Gguw%3D%3D (Pubitemid 11094651)
2. VP Werth 2005 Clinical manifestations of cutaneous lupus erythematosus Autoimmun Rev 4 296 302 15990077 10.1016/j.autrev.2005.01.003 (Pubitemid 40884548)
3. HJ Lee AA Sinha 2006 Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies Autoimmunity 39 433 444 17060022 10.1080/08916930600886851 1:CAS:528:DC%2BD28Xhtlagu7rM (Pubitemid 44575075)
4. •• Fett N, Werth VP (2011, In press) Treatment of cutaneous lupus erythematosus. In: Maibach H, editor. Evidence Based Dermatology. 2nd ed. This is a thorough, evidence-based review of treatments used in CLE. It addresses treatment efficacy by focusing on level of evidence as well as study design and outcome measures. It includes a focused summary section on the level of evidence for different treatments used.
5. •• Kuhn A, Ruland V, Bonsmann G (2010) Cutaneous lupus erythematosus: update of therapeutic options part I and part II. J Am Acad Dermatol. This is a comprehensive and detailed two-part review of treatment options, including details on CLE subtypes and medication dosing used in studies. It provides a diagrammatic treatment algorithm.
6. JP Callen 2006 Cutaneous lupus erythematosus: a personal approach to management Australas J Dermatol 47 13 27 16405478 10.1111/j.1440-0960.2006. 00217.x
7. O Durosaro MD Davis KB Reed AL Rohlinger 2009 Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study Arch Dermatol 145 249 253 19289752 10.1001/archdermatol.2009.21
8. RS Klein VP Werth JC Dowdy RM Sayre 2009 Analysis of compact fluorescent lights for use by patients with photosensitive conditions Photochem Photobiol 85 1004 1010 19320850 10.1111/j.1751-1097.2009.00540.x 1:CAS:528: DC%2BD1MXovVGqtLg%3D
9. H Stege MA Budde S Grether-Beck J Krutmann 2000 Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test Photodermatol Photoimmunol Photomed 16 256 259 11132128 10.1034/j.1600-0781.2000.160604.x 1:CAS:528:DC%2BD3cXptVSjsLw%3D
10. BL Diffey 2001 Sun protection with clothing Br J Dermatol 144 449 450 11259996 10.1046/j.1365-2133.2001.04122.x 1:STN:280:DC%2BD3M7mtFCrsA%3D%3D (Pubitemid 32231994)
11. HH Roenigk Jr JS Martin P Eichorn JN Gilliam 1980 Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy Cutis 25 281 285 6987043 (Pubitemid 10128832)
12. J Hughes M Rustin 1997 Corticosteroids Clin Dermatol 15 715 721 9313970 10.1016/S0738-081X(97)00020-5 1:STN:280:DyaK2svlvFWqtw%3D%3D (Pubitemid 27411305)
13. TY Tzung YS Liu HW Chang 2007 Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study Br J Dermatol 156 191 192 17199600 10.1111/j.1365-2133.2006.07595.x 1:CAS:528:DC%2BD2sXhsVOnt7w%3D (Pubitemid 44924177)
14. V Madan PJ August RJ Chalmers 2010 Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study Clin Exp Dermatol 35 27 30 19549244 10.1111/j.1365-2230.2009.03351.x 1:STN:280:DC%2BD1MfjslKrtA%3D%3D
15. B Barikbin S Givrad M Yousefi F Eskandari 2009 Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study Clin Exp Dermatol 34 776 780 19456797 10.1111/j.1365-2230.2008.03138.x 1:STN:280: DC%2BD1Mnhs1yqtw%3D%3D
16. M Sardy T Ruzicka A Kuhn 2009 Topical calcineurin inhibitors in cutaneous lupus erythematosus Arch Dermatol Res 301 93 98 18797893 10.1007/s00403-008- 0894-6 1:CAS:528:DC%2BD1cXhsFejt77N
17. D Thaci R Salgo 2010 Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies Clin Dermatol 28 52 56 20082951 10.1016/j.clindermatol.2009.04.001
18. GB Jemec S Ullman M Goodfield A Bygum AB Olesen, et al. 2009 A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus Br J Dermatol 161 1365 1370 19681862 10.1111/j.1365-2133.2009. 09330.x 1:CAS:528:DC%2BC3cXkvFOnsw%3D%3D
19. A Erceg HJ Bovenschen PC van de Kerkhof EM de Jong MM Seyger 2009 Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus J Am Acad Dermatol 60 626 632 19293010 10.1016/j.jaad.2008.11.904
20. S Kalia JP Dutz 2007 New concepts in antimalarial use and mode of action in dermatology Dermatol Ther 20 160 174 17970883 10.1111/j.1529-8019.2007.00131. x (Pubitemid 350029307)
21. A Wozniacka A Carter DP McCauliffe 2002 Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit Lupus 11 71 81 11958581 10.1191/0961203302lu147rr 1:CAS:528:DC%2BD38Xjt1Chtbg%3D (Pubitemid 34259436)
22. T Ruzicka C Sommerburg G Goerz P Kind H Mensing 1992 Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine Br J Dermatol 127 513 518 1467292 10.1111/j.1365-2133.1992.tb14851.x 1:STN:280:DyaK3s7gsVWrtQ%3D%3D
23. EL Bezerra MJ Vilar PB da Trindade Neto EI Sato 2005 Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus Arthritis Rheum 52 3073 3078 16200586 10.1002/art.21358 1:CAS:528:DC%2BD2MXhtF2msrrJ (Pubitemid 41447088)
24. I Cavazzana R Sala C Bazzani A Ceribelli C Zane, et al. 2009 Treatment of lupus skin involvement with quinacrine and hydroxychloroquine Lupus 18 735 739 19502270 10.1177/0961203308101714 1:CAS:528:DC%2BD1MXptVOjtbg%3D
25. R Feldmann D Salomon JH Saurat 1994 The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus Dermatology 189 425 427 7873836 10.1159/000246899 1:STN:280:DyaK2M7nvVOqsQ%3D%3D (Pubitemid 24358003)
26. D Lipsker JC Piette P Cacoub P Godeau C Frances 1995 Chloroquine- quinacrine association in resistant cutaneous lupus Dermatology 190 257 258 7599397 10.1159/000246710 1:STN:280:DyaK2Mzit1Krsw%3D%3D
27. JM Tripp HI Maibach 2006 Hydroxychloroquine-induced retinopathy: a dermatologic perspective Am J Clin Dermatol 7 171 175 16734504 10.2165/00128071-200607030-00003 (Pubitemid 43845341)
28. Chang AY, Piette E, Foering KP, Okawa J, Werth VP. Response to antimalarials in cutaneous lupus erythematosus. J Invest Dermatol (abstract). 2011;131 Suppl 1:S80.
29. JP Callen 1982 Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients Arch Dermatol 118 412 416 7092253 10.1001/archderm.118.6.412 1:STN:280:DyaL383ivF2nsw%3D%3D (Pubitemid 12116650)
30. L Biro N Leone 1965 Aplastic anemia induced by quinacrine Arch Dermatol 92 574 576 5844404 10.1001/archderm.1965.01600170090017 1:STN:280: DyaF28%2Fkt1OltA%3D%3D
31. MF Marmor RE Carr M Easterbrook AA Farjo WF Mieler 2002 Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology Ophthalmology 109 1377 1382 12093666 10.1016/S0161-6420(02)01168-5 (Pubitemid 34700934)
32. ML Jewell DP McCauliffe 2000 Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment J Am Acad Dermatol 42 983 987 10827400 10.1016/S0190-9622(00)90290-1 1:STN:280:DC%2BD3c3oslKisA%3D%3D (Pubitemid 30368665)
33. A Kreuter R Gaifullina C Tigges J Kirschke P Altmeyer, et al. 2009 Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking Arch Dermatol 145 244 248 19289751 10.1001/archdermatol. 2008.592 1:CAS:528:DC%2BD1MXkt1eiurY%3D
34. P Rahman DD Gladman MB Urowitz 1998 Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus J Rheumatol 25 1716 1719 9733451 1:STN:280:DyaK1cvgt1artQ%3D%3D (Pubitemid 28439264)
35. IB Boehm GA Boehm R Bauer 1998 Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms Rheumatol Int 18 59 62 9782534 10.1007/s002960050058 1:CAS:528:DyaK1cXnslCgtb4%3D (Pubitemid 28432835)
36. J Wenzel S Brahler R Bauer T Bieber T Tuting 2005 Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients Br J Dermatol 153 157 162 16029342 10.1111/j.1365-2133.2005.06552.x 1:CAS:528:DC%2BD2MXps1Knt7w%3D (Pubitemid 41044542)
37. A Kreuter NS Tomi SM Weiner M Huger P Altmeyer, et al. 2007 Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy Br J Dermatol 156 1321 1327 17408395 10.1111/j.1365-2133.2007.07826.x 1:CAS:528:DC%2BD2sXot1Witrc%3D (Pubitemid 47029802)
38. R Ashinoff VP Werth AG Franks Jr 1988 Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine J Am Acad Dermatol 19 961 965 3192780 10.1016/S0190-9622(88)70259-5 1:STN:280:DyaL1M%2FlsVGhsA%3D%3D (Pubitemid 18266023)
39. Alsanafi S, Kovarik C, Mermelstein AL, Werth VP. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol. 2011;17 3:142-4.
40. M Chen SD Doherty S Hsu 2010 Innovative uses of thalidomide Dermatol Clin 28 577 586 20510766 10.1016/j.det.2010.03.003 1:CAS:528:DC%2BC3cXosFeqsr4%3D
41. JB Zeldis BA Williams SD Thomas ME Elsayed 1999 S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide Clin Ther 21 319 330 10211535 10.1016/S0149-2918(00)88289-2 1:STN:280: DyaK1M3is1GitQ%3D%3D (Pubitemid 29157790)
42. SC Apfel DW Zochodne 2004 Thalidomide neuropathy: too much or too long? Neurology 62 2158 2159 15210874 (Pubitemid 38787767)
43. DJ Wallace M Linker-Israeli AL Metzger VJ Stecher 1993 The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE Lupus 2 Suppl 1 S13 15 8485565 10.1177/096120339300200104
44. A Shah J Albrecht Z Bonilla-Martinez J Okawa M Rose, et al. 2009 Lenalidomide for the treatment of resistant discoid lupus erythematosus Arch Dermatol 145 303 306 19289762 10.1001/archdermatol.2009.30 1:CAS:528: DC%2BD1MXkt1eiu7g%3D
45. AP Fernandez FA Kerdel 2007 The use of i.v. IG therapy in dermatology Dermatol Ther 20 288 305 17970894 10.1111/j.1529-8019.2007.00142.x (Pubitemid 350029317)
46. J Albrecht L Taylor JA Berlin S Dulay G Ang, et al. 2005 The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus J Invest Dermatol 125 889 894 16297185 1:CAS:528:DC%2BD2MXht1GrtrzE
47. MS Krathen J Dunham E Gaines J Junkins-Hopkins E Kim, et al. 2008 The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology Arthritis Rheum 59 338 344 18311759 10.1002/art.23319 1:STN:280:DC%2BD1c7pvFyrtQ%3D%3D (Pubitemid 351399203)
48. R Klein S Moghadam-Kia J LoMonico J Okawa C Coley, et al. 2011 Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus Arch Dermatol 147 203 8 21339447 10.1001/archdermatol.2010.435
49. A Kuhn E Kuehn AM Meuth M Haust F Nyberg, et al. 2009 Development of a core set questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Autoimmun Rev 8 702 712 19232553 10.1016/j.autrev.2009.02.022 1:STN:280:DC%2BD1MvhvFemtA%3D%3D
50. AY Finlay 1996 Measurement of disease activity and outcome in atopic dermatitis Br J Dermatol 135 509 515 8915137 10.1111/j.1365-2133.1996.tb03822.x 1:STN:280:DyaK2s%2Fnt1eksw%3D%3D (Pubitemid 26340258)
51. J Albrecht VP Werth 2007 Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus Dermatol Ther 20 93 101 17537137 10.1111/j.1529-8019.2007.00117.x (Pubitemid 46817424)
52. A Kuhn S Amler S Beissert M Bohm R Brehler, et al. 2010 Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus Br J Dermatol 163 83 92 20394621 1:STN:280:DC%2BC3cjgslWksw%3D%3D